The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
Seyeon ParkJeongha Mok

Abstract

The use of bedaquiline to treat patients with multidrug-resistant tuberculosis (MDR-TB) and end-stage renal disease (ESRD) may raise safety concerns. Currently, no clinical information is available on the use of bedaquiline to treat MDR-TB patients with ESRD. We report the use of bedaquiline to treat two patients with MDR-TB and ESRD. This report highlights the safety and tolerability of bedaquiline as well as the treatment outcome. The use of bedaquiline in patients with ESRD is also discussed.

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Related Papers

Advances in Renal Replacement Therapy
C Thomas
The European Respiratory Journal
Anne-Fleur Louise Van der PaardtJan-Willem C Alffenaar
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
L WolfsonG Knerer
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Yusuke Tsukamoto
The European Respiratory Journal
Lorenzo GuglielmettiMDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Coh
© 2022 Meta ULC. All rights reserved